Dr. Cavo - ASH 2008 - Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma; Up-Front Response Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities
Michele Cavo, MD Bologna University School of Medicine Seragnoli Institute of Hematology and Medical Oncology Bologna, Italy
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.